21, October 2014

AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has conditionally, raised approximately £3.4 million. This is principally...

Click here for more details

21, October 2014

ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is proud to announce that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma&...

Click here for more details

02, October 2014

Lupuzor™ Gears Up To Start Pivotal Phase III trials

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon c...

Click here for more details

02, October 2014

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014.KEY HIGHLIGHTS&bu...

Click here for more details

27, June 2014

ANNUAL GENERAL MEETING: 2014

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A sum...

Click here for more details

27, June 2014

ImmuPharma to access pioneering research in the Bordeaux region of France

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, workin...

Click here for more details

16, June 2014

New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is delighted to announce that the US Patent and Trademark Office has granted a notice of allowance...

Click here for more details

09, June 2014

PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2013.Key Hig...

Click here for more details

23, May 2014

Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014

ImmuPharma PLC (AIM:IMM) (the “Company”)  the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2013 will be posted to shareholders today....

Click here for more details

06, May 2014

Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides a summary of the presentation given by Dr. Slyviane Muller at the European Lupus Confere...

Click here for more details

23, April 2014

Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that Dr. Sylviane Muller was recently invited by the Immunology Frontier R...

Click here for more details

11, April 2014

ImmuPharma Sponsors the 2014 European Lupus Conference

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes...

Click here for more details